Titan Medical (NASDAQ:TMDI) and Tandem Diabetes Care (NASDAQ:TNDM) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations and price targets for Titan Medical and Tandem Diabetes Care, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Titan Medical 0 1 2 0 2.67
Tandem Diabetes Care 0 5 8 0 2.62

Titan Medical presently has a consensus price target of $1.50, indicating a potential upside of 858.47%. Tandem Diabetes Care has a consensus price target of $84.67, indicating a potential upside of 47.25%. Given Titan Medical’s stronger consensus rating and higher probable upside, analysts plainly believe Titan Medical is more favorable than Tandem Diabetes Care.

Risk and Volatility

Titan Medical has a beta of 4.15, meaning that its stock price is 315% more volatile than the S&P 500. Comparatively, Tandem Diabetes Care has a beta of 0.2, meaning that its stock price is 80% less volatile than the S&P 500.


This table compares Titan Medical and Tandem Diabetes Care’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Titan Medical N/A N/A -165.51%
Tandem Diabetes Care -6.83% -8.99% -5.19%

Valuation and Earnings

This table compares Titan Medical and Tandem Diabetes Care’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Titan Medical N/A N/A -$22.64 million ($1.36) -0.12
Tandem Diabetes Care $362.30 million 9.48 -$24.75 million ($0.22) -261.36

Titan Medical has higher earnings, but lower revenue than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

5.1% of Titan Medical shares are held by institutional investors. Comparatively, 90.9% of Tandem Diabetes Care shares are held by institutional investors. 6.9% of Tandem Diabetes Care shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.


Titan Medical beats Tandem Diabetes Care on 7 of the 13 factors compared between the two stocks.

Titan Medical Company Profile

Titan Medical Inc., a research and development stage company, focuses on the design, development, and commercialization of computer-assisted robotic surgical technologies for application in minimally invasive surgery (MIS). The company is developing the SPORT Surgical System, a single-port robotic surgical system that comprises a surgeon-controlled patient cart, which includes a 3D vision system and multi-articulating instruments for performing MIS procedures; and a surgeon workstation that provides the surgeon with ergonomic interface to the patient cart and a 3D endoscopic view inside the patient's body during MIS procedures. The SPORT Surgical System enables surgeons to perform surgical procedures for gynecologic, urologic, colorectal, and general abdominal indications. Titan Medical Inc. is headquartered in Toronto, Canada.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 Insulin Delivery System with Basal-IQ Technology; t:slim X2 with G5 Integration; and Tandem Device Updater that allows users to update their pump's software. In addition, the company offers t:connect diabetes management application, a cloud-based data management application, which provides a visual way to display therapy management data from the pump and supported blood glucose meters for users, their caregivers, and their healthcare providers; and various pump accessories. Its products in development include t:slim X2 with control IQ technology; t:sport insulin delivery system; and connected (mobile) health offerings. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was founded in 2006 and is headquartered in San Diego, California.

Receive News & Ratings for Titan Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Medical and related companies with MarketBeat.com's FREE daily email newsletter.